Nichols Derek A, Renslo Adam R, Chen Yu
University of South Florida College of Medicine, Department of Molecular Medicine, 12901 Bruce B. Downs Blvd, MDC 3522, Tampa, FL 33612, USA.
Future Med Chem. 2014 Mar;6(4):413-27. doi: 10.4155/fmc.14.10.
The production of β-lactamase is one of the primary resistance mechanisms used by Gram-negative bacterial pathogens to counter β-lactam antibiotics, such as penicillins, cephalosporins and carbapenems. There is an urgent need to develop novel β-lactamase inhibitors in response to ever evolving β-lactamases possessing an expanded spectrum of β-lactam hydrolyzing activity. Whereas traditional high-throughput screening has proven ineffective against serine β-lactamases, fragment-based approaches have been successfully employed to identify novel chemical matter, which in turn has revealed much about the specific molecular interactions possible in the active site of serine and metallo β-lactamases. In this review, we summarize recent progress in the field, particularly: the identification of novel inhibitor chemotypes through fragment-based screening; the use of fragment-protein structures to understand key features of binding hot spots and inform the design of improved leads; lessons learned and new prospects for β-lactamase inhibitor development using fragment-based approaches.
β-内酰胺酶的产生是革兰氏阴性细菌病原体对抗β-内酰胺抗生素(如青霉素、头孢菌素和碳青霉烯类)的主要耐药机制之一。鉴于不断出现具有更广谱β-内酰胺水解活性的β-内酰胺酶,迫切需要开发新型β-内酰胺酶抑制剂。传统的高通量筛选已证明对丝氨酸β-内酰胺酶无效,而基于片段的方法已成功用于鉴定新型化学物质,这反过来又揭示了许多关于丝氨酸和金属β-内酰胺酶活性位点可能存在的特定分子相互作用的信息。在本综述中,我们总结了该领域的最新进展,特别是:通过基于片段的筛选鉴定新型抑制剂化学类型;利用片段-蛋白质结构来理解结合热点的关键特征并为改进先导化合物的设计提供信息;使用基于片段的方法开发β-内酰胺酶抑制剂的经验教训和新前景。